FDA Approves 30-Minute Steam Treatment for Prostate Cancer

Prostate cancer patients now have a gentler option that takes less than an hour and lets them go home the same day.

Francis Medical, a medical device company in Maple Grove, Minnesota, just received FDA approval for its Vanquish Water Vapor Ablation System. The technology uses precisely targeted steam to kill cancer cells while protecting surrounding healthy tissue and nerves.

The treatment represents eight years of development finally reaching patients who need it most. Instead of surgery or lengthy radiation therapy, eligible patients can now receive a steam-based procedure in an outpatient setting that typically lasts between 30 and 60 minutes.

Here's how it works: doctors use the Vanquish system to deliver water vapor directly to cancerous tissue in the prostate. The steam carries thermal energy that causes rapid cell death in tumors while significantly limiting damage to nearby areas.

The precision matters enormously for quality of life. Traditional treatments often cause complications that affect daily living, but the targeted steam approach reduces those side effects considerably.

Mike Kujak, President and CEO of Francis Medical, believes the technology will transform cancer care globally. "I have great hope that it will become, worldwide, the standard of care," he said.

The treatment works best for localized cancer contained within the prostate. That might sound limiting, but it actually applies to most patients who walk through the door.

Approximately 84% of prostate cancer cases are diagnosed while still contained within the prostate. For those patients, the Vanquish system offers a solution that balances effectiveness with preservation of normal function.

Kujak acknowledges the technology isn't right for everyone. Patients with cancer that has spread beyond the prostate will need different approaches, but the vast majority of newly diagnosed patients could benefit.

The Ripple Effect

This approval arrives at a crucial time. Prostate cancer remains one of the most common cancers affecting men, with hundreds of thousands of new diagnoses each year in the United States alone.

Every patient who can avoid invasive surgery or extensive radiation represents not just a medical win, but a quality of life victory. Fewer side effects mean more time working, spending time with family, and living normally during and after treatment.

The outpatient nature of the procedure also reduces strain on hospital systems. Shorter treatment times and no overnight stays mean more patients can access care without lengthy waits or complicated scheduling.

With FDA approval secured, Francis Medical is now focused on making the technology available to cancer centers nationwide. The company's commercial expansion means patients across the country could soon have access to this option.

For the 84% of prostate cancer patients whose disease is caught early and contained, hope now comes in the form of steam, precision, and a same-day trip home.